On Wednesday, 16th June 2021, the Swiss drug making company Novartis AG has received the breakthrough therapy designation from the Food and Drug Administration (FDA) of the United States of America for the purpose of an experimental treatment for the advanced castration-resistant prostate cancer.
The men suffering from the prostate cancer, which has been spread in them and the men were not being helped by the other treatments on the average have survived for four months more after receiving the Lu-PSMA-617 of Novartis, a tumor targeting radiation therapy, than the men, who received standard care.
The breakthrough therapy of the company Novartis attaches a radioactive isotope, lutetium-177, along with a half life of the people less than seven days, with a small molecule drug known as PSMA-617, that has been responsible in binding to an antigen, that has been expressed in larger amounts by the cells of the prostrate cancer, and the therapy is also aiming to kill the cancer cells in a targeted way.
The breakthrough designation of the FDA is going to be used for helping the expedite development along with the review of the therapies, that has been demonstrating the potential for the substantial improvement over the available treatments, and the company Novartis, that has acquired the therapy with the company’s $2.1-billion purchase of the Endocyte, is having a portfolio of the radioligand medicines, that has been including the already approved the carcer therapy known as Lutathera.
The prostate cancer can also be treated through undergoing a surgery, along with the radiation therapy and also through the hormone therapy, which are helpful in stopping the production of the testosterone, that drives the tumor.
